Short answer
Guardant Health, Inc. (GH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Guardant Health announced financial results for the quarter ended September 30, 2026.
Guardant Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Guardant Health announced financial results for the quarter ended September 30, 2026
- Detailed revenue, earnings, cash flow and guidance information appears in Exhibit 99.1
- Results provide the latest update on operating performance and financial condition for investors
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $361.0M, up 36%, led by Oncology revenue $231.3M and Screening revenue $67.6M, up 180%
- Test volumes accelerated: Oncology 117,000, up 58%, and Shield 83,000, up 246% year over year
- 2026 revenue guidance raised to $1.36B-$1.37B, growth of 38%-40%, with Shield revenue guidance increased to $233M-$238M
- Non-GAAP gross margin improved to 67% from 66%, while operating investment increased and GAAP net loss widened to $124.4M
- Cash, cash equivalents and restricted cash $1.1B, but full-year free-cash-flow burn guidance increased to $205M-$220M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Guardant Health, Inc. 8-K filings
Get the next GH 8-K as it lands
Follow GH for push alerts, or ask the research agent what this filing means.